0001104659-20-015172.txt : 20200210 0001104659-20-015172.hdr.sgml : 20200210 20200210202700 ACCESSION NUMBER: 0001104659-20-015172 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200206 FILED AS OF DATE: 20200210 DATE AS OF CHANGE: 20200210 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Schroeder Theodore R CENTRAL INDEX KEY: 0001378690 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37558 FILM NUMBER: 20593550 MAIL ADDRESS: STREET 1: 12481 HIGH BLUFF DRIVE, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Nabriva Therapeutics plc CENTRAL INDEX KEY: 0001641640 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 56 FITZWILLIAM SQUARE CITY: DUBLIN STATE: L2 ZIP: 2 BUSINESS PHONE: (610) 816-6640 MAIL ADDRESS: STREET 1: 1000 CONTINENTAL DRIVE STREET 2: SUITE 600 CITY: KING OF PRUSSIA STATE: PA ZIP: 19406 FORMER COMPANY: FORMER CONFORMED NAME: Nabriva Therapeutics AG DATE OF NAME CHANGE: 20150507 4 1 a4.xml 4 X0306 4 2020-02-06 0 0001641640 Nabriva Therapeutics plc NBRV 0001378690 Schroeder Theodore R 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406 1 1 0 0 Chief Executive Officer Ordinary Shares 2020-02-06 4 A 0 343800 0 A 646560 D Stock Options 1.35 2020-02-06 4 A 0 687500 0 A 2030-02-05 Ordinary Shares 687500 687500 D The reported transaction involved the reporting person's receipt of a grant of 343,800 restricted stock units. The total reported in Column 5 includes the 343,800 newly awarded restricted stock units. The option was granted on February 6, 2020, subject to shareholder approval; provided, that if such shareholder approval is not obtained, the option will remain outstanding and convert into a cash-settled share appreciation right. The option will vest over a four-year period beginning on February 6, 2020. Twenty-five percent (25%) of the option will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the option will vest on a monthly pro-rata basis over the remaining vesting period. /s/ Robert Crotty, by power of attorney 2020-02-10